GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Additional Paid-In Capital

Zymeworks (FRA:ZA8) Additional Paid-In Capital : €131.69 Mil(As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Additional Paid-In Capital?


Zymeworks's quarterly additional paid-in capital declined from Sep. 2023 (€144.41 Mil) to Dec. 2023 (€130.47 Mil) but then increased from Dec. 2023 (€130.47 Mil) to Mar. 2024 (€131.69 Mil).

Zymeworks's annual additional paid-in capital declined from Dec. 2021 (€174.97 Mil) to Dec. 2022 (€143.12 Mil) and declined from Dec. 2022 (€143.12 Mil) to Dec. 2023 (€130.47 Mil).

Zymeworks Additional Paid-In Capital Historical Data

The historical data trend for Zymeworks's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Additional Paid-In Capital Chart

Zymeworks Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.56 134.50 174.97 143.12 130.47

Zymeworks Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.60 140.53 144.41 130.47 131.69

Zymeworks Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Zymeworks Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zymeworks's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (FRA:ZA8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Additional Paid-In Capital
Comparable Companies
AUTL VERA ALPN ALLO TARS TBPH TYRA ELVN SVRA ARCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ZYME:USA
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Website
https://www.zymeworks.com
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines